A retrospective study of biosimilar infliximab for the treatment of non-infectious uveitis in Central Norway Health Region
Latest Information Update: 10 Aug 2021
Price :
$35 *
At a glance
- Drugs Infliximab (Primary)
- Indications Anterior uveitis; Uveitis
- Focus Adverse reactions
- 10 Aug 2021 New trial record